Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 PK, safety and tolerability of single-dose amlitelimab (SAR445229) in healthy Chinese and Japanese adults
jRCT2071220049Phase 1Completed
- Sponsor
- Sanofi
- Start
- Sep 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 1, randomised, open-label trial of amlitelimab, sponsored by Sanofi. Primary endpoint: Primary PK parameters. Started Sep 2022; status: completed.
02
Drugs
amlitelimab
Beyond the preview
Go deeper on jRCT2071220049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071220049.